Prithviraj Bose, Zhijian Xiao, Hans C Hasselbalch, Josef T Prchal, Minghui Duan, Abdulraheem Yacoub, Raajit Rampal, Jean-Jacques Kiladjian, Gabriela S Hobbs, Tsewang Tashi, Kazuya Shimoda, Keita Kirito, Harinder Gill, Hsin-An Hou, Sung-Eun Lee, Jian Huang, Bing Li, Albert Qin, Lennex Hsueh-Lin Yu, John O Mascarenhas, Ruben A Mesa
{"title":"Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms.","authors":"Prithviraj Bose, Zhijian Xiao, Hans C Hasselbalch, Josef T Prchal, Minghui Duan, Abdulraheem Yacoub, Raajit Rampal, Jean-Jacques Kiladjian, Gabriela S Hobbs, Tsewang Tashi, Kazuya Shimoda, Keita Kirito, Harinder Gill, Hsin-An Hou, Sung-Eun Lee, Jian Huang, Bing Li, Albert Qin, Lennex Hsueh-Lin Yu, John O Mascarenhas, Ruben A Mesa","doi":"10.1007/s11899-025-00752-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>This report summarizes key insights from the 8th Annual International Symposium on Myeloproliferative Neoplasms (MPN Asia 2025). The symposium brought together global experts to discuss advancements in MPN biology, diagnostics, and therapeutics, with a focus on emerging molecular understanding, novel treatment strategies and real-world data.</p><p><strong>Recent findings: </strong>Molecular profiling has become essential in MPN risk stratification and therapeutic decision-making. High-risk mutations (e.g., ASXL1, TP53) and inflammatory pathways (e.g., IL-17, NF-κB) were shown to correlate with disease progression and transformation. Interferon-based therapy is increasingly used in younger, low-risk, or treatment-naïve patients, and is also being investigated in myelofibrosis and essential thrombocythemia. Ropeginterferon alfa-2b, a novel interferon-based therapy, demonstrated durable clinical efficacy in polycythemia vera. Its high initial-dose and accelerated titration (HIDAT) regimen led to fast achievement of complete hematologic response, rapid reductions in JAK2V617F allele burden, and high complete molecular response rate. Combination regimens involving ruxolitinib and agents such as pelabresib, selinexor, and interferon showed potential for enhanced efficacy. Population-based studies from Asia contributed regional epidemiological and treatment data, reinforcing the role of real-world evidence. Modern prognostic models such as MIPSS70+ v2.0 and GIPSS were discussed for more precise risk prediction. Preliminary findings also suggest ropeginterferon alfa-2b may be a safe option during pregnancy. MPN Asia 2025 highlighted the growing role of molecular diagnostics and targeted therapeutics in the management of MPNs. Ropeginterferon alfa-2b has emerged as a therapeutic potential across the MPN spectrum. Its early use and personalized strategies are increasingly recognized. Real-world data and regional insights are shaping a more nuanced, globally informed approach to MPN care.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"20 1","pages":"9"},"PeriodicalIF":2.7000,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254180/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hematologic Malignancy Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11899-025-00752-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose of review: This report summarizes key insights from the 8th Annual International Symposium on Myeloproliferative Neoplasms (MPN Asia 2025). The symposium brought together global experts to discuss advancements in MPN biology, diagnostics, and therapeutics, with a focus on emerging molecular understanding, novel treatment strategies and real-world data.
Recent findings: Molecular profiling has become essential in MPN risk stratification and therapeutic decision-making. High-risk mutations (e.g., ASXL1, TP53) and inflammatory pathways (e.g., IL-17, NF-κB) were shown to correlate with disease progression and transformation. Interferon-based therapy is increasingly used in younger, low-risk, or treatment-naïve patients, and is also being investigated in myelofibrosis and essential thrombocythemia. Ropeginterferon alfa-2b, a novel interferon-based therapy, demonstrated durable clinical efficacy in polycythemia vera. Its high initial-dose and accelerated titration (HIDAT) regimen led to fast achievement of complete hematologic response, rapid reductions in JAK2V617F allele burden, and high complete molecular response rate. Combination regimens involving ruxolitinib and agents such as pelabresib, selinexor, and interferon showed potential for enhanced efficacy. Population-based studies from Asia contributed regional epidemiological and treatment data, reinforcing the role of real-world evidence. Modern prognostic models such as MIPSS70+ v2.0 and GIPSS were discussed for more precise risk prediction. Preliminary findings also suggest ropeginterferon alfa-2b may be a safe option during pregnancy. MPN Asia 2025 highlighted the growing role of molecular diagnostics and targeted therapeutics in the management of MPNs. Ropeginterferon alfa-2b has emerged as a therapeutic potential across the MPN spectrum. Its early use and personalized strategies are increasingly recognized. Real-world data and regional insights are shaping a more nuanced, globally informed approach to MPN care.
回顾目的：本报告总结了第八届骨髓增殖性肿瘤国际研讨会（MPN Asia 2025）的主要见解。研讨会汇集了全球专家，讨论MPN生物学，诊断和治疗方面的进展，重点是新兴的分子理解，新的治疗策略和现实世界的数据。最近发现：分子谱分析在MPN风险分层和治疗决策中已成为必不可少的。高风险突变（如ASXL1、TP53）和炎症通路（如IL-17、NF-κB）与疾病进展和转化相关。基于干扰素的治疗越来越多地用于年轻、低风险或treatment-naïve患者，也正在研究用于骨髓纤维化和原发性血小板增多症。ropeg干扰素α -2b是一种新的干扰素治疗方法，在真性红细胞增多症中显示出持久的临床疗效。其高初始剂量和加速滴定（HIDAT）方案可快速实现完全血液学反应，快速降低JAK2V617F等位基因负担，并具有高完全分子反应率。包括鲁索利替尼和诸如培拉瑞昔布、selinexor和干扰素等药物的联合治疗方案显示出增强疗效的潜力。来自亚洲的基于人群的研究提供了区域流行病学和治疗数据，加强了真实世界证据的作用。讨论了现代预后模型，如MIPSS70+ v2.0和GIPSS，以更精确地预测风险。初步研究结果还表明，ropeginterferon α -2b在怀孕期间可能是安全的选择。MPN Asia 2025强调了分子诊断和靶向治疗在MPN治疗中的日益重要的作用。聚乙二醇干扰素α -2b已成为跨MPN谱的治疗潜力。它的早期使用和个性化策略越来越得到认可。真实世界的数据和区域见解正在形成一种更加细致入微、全球知情的MPN护理方法。
期刊介绍：
his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy.
We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
